4//SEC Filing
MCKEREGHAN KATHLEEN 4
Accession 0001209191-10-052014
CIK 0001298521other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 6:01 PM ET
Size
17.5 KB
Accession
0001209191-10-052014
Insider Transaction Report
Form 4
MCKEREGHAN KATHLEEN
SVP and General Counsel
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−65,000→ 0 totalExercise: $17.53Exp: 2017-07-19→ Common Stock (65,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−50,000→ 0 totalExercise: $1.33Exp: 2019-01-30→ Common Stock (50,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−27,500→ 0 totalExercise: $1.33Exp: 2019-01-30→ Common Stock (27,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−20,600→ 0 totalExercise: $8.98Exp: 2018-01-31→ Common Stock (20,600 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2010-10-28−45,000→ 0 totalExercise: $3.82Exp: 2020-01-29→ Common Stock (45,000 underlying)
Holdings
- 0
Common Stock
Footnotes (5)
- [F1]This option, which provided for vesting at the rate of 25% on June 26, 2008, and 1/48th monthly thereafter, such that all of the shares would be fully vested as of June 26, 2011, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F2]This option, which provided for vesting at the rate of 1/48th on February 1, 2008, and 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2012, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F3]This option, which provided for vesting at the rate of 1/48th on February 1, 2009, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $161,000, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 50,000 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F4]This option. which provided for vesting at the rate of 1/36th on August 27, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of July 27, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $88,550, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 27,500 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F5]This option, which provided for vesting at the rate of 1/48th on February 1, 2010, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2014, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $32,850, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 45,000 contingent value rights, which represents the right to receive possible additional future cash payments.
Documents
Issuer
Trubion Pharmaceuticals, Inc
CIK 0001298521
Entity typeother
Related Parties
1- filerCIK 0001229761
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 6:01 PM ET
- Size
- 17.5 KB